fep blue glp 1 coverage 2026 CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug FEP Blue update to PA

2 In this context, obesity, with its extensive systemic effects, is identified as a major fertility disruptor either alone or in combination with polycystic ovary syndrome (PCOS)

Mounjaro and Zepbound contain tirzepatide, which targets that hormone plus another one involved in metabolism

Kato S, et al

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Because even as branded drugs become more available and potentially cheaper, the same coverage restrictions, BMI cutoffs, and off-label barriers remain